Clinical trial NCT02861365: Myocardial Perfusion and Scarring in Adults With Congenital Heart Disease
Official title: Quantitative Myocardial Perfusion, Myocardial Scarring and Their Contribution to Late Clinical Decompensation in Adults With Congenital Heart Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiac Disease
Lead sponsor: Children's National Research Institute
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2016-08-10
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: This is a study of the perfusion of the myocardium in adults with specific forms of repaired congenital heart disease using established cardiac MRI techniques and correlating perfusion with clinical outcomes.

Detailed description: This is a study of the perfusion of the myocardium in adults with specific forms of repaired congenital heart disease using established cardiac MRI techniques and correlating perfusion with clinical outcomes. The investigators objectives are to examine myocardial perfusion both during stress and at rest in adults with repaired or palliated congenital heart disease as well as quantify ventricular function, regional myocardial strain and evidence of myocardial fibrosis with quantitative measures of myocardial perfusion. The specific aim of this study is to understand whether clinical subendocardial perfusion defects contribute to the late decompensation of adult subjects that have single ventricle physiology and adult subjects that have a systemic right ventricle.

Eligibility criteria: Inclusion Criteria:

* Subjects 18 years of age or older
* All defects that have a right ventricle that supports the systemic circulation
* All defects with a functional single ventricle
* Written informed consent

Exclusion Criteria:

* Subjects with a contraindication to magnetic resonance imaging (MRI) scanning will be excluded. These contraindications include subjects with the following devices:

  * Central nervous system aneurysm clips
  * Implanted neural stimulator
  * Implanted cardiac pacemaker or defibrillator
  * Cochlear implant
  * Ocular foreign body (e.g. metal shavings)
  * Implanted Insulin pump
  * Metal shrapnel or bullet
* Severe heart damage that makes it difficult to breathe while lying flat
* Pregnant women (Women of childbearing potential who are uncertain as to whether they are pregnant will be required to have a screening urine or blood pregnancy test)
* Subjects with active symptoms of myocardial ischemia occurring despite maximally tolerated doses of oral antianginal therapy and intravenous nitroglycerin
* Furthermore, the following subject groups will be excluded from studies involving the administration of MRI contrast agents:

  * lactating women unless they are willing to discard breast milk for 24 hours after receiving gadolinium
  * renal disease (estimated glomerular filtration rate \[eGFR\] \< 30 ml/min/1.73 m2 body surface area)

The eGFR will be used to estimate renal function if reported by the laboratory. Otherwise, estimated glomerular filtration rate (eGFR) can be based on the Modification of Diet in Renal Disease (MDRD) study equation (see below) in subjects with stable renal function. This formula is not applicable to subjects with acute renal insufficiency:

eGFR (ml/min/1.73 m2) = 175 x (serum creatinine)-1.154 x (age)-0.203 x 0.742 (if the subject is female) x 1.212 (if the subject is black)

Additional Exclusion Criteria for Vasodilator Stress MRI:

* Myocardial infarction within 24 hours
* Uncontrolled heart failure
* Uncontrolled asthma or emphysema
* Ventricular arrhythmia (sustained ventricular arrhythmia at the time of MR scan)
* Second degree heart block or higher

Primary outcomes:
measure: Myocardial Ischemia measuring coronary perfusion reserve.
timeFrame: 5 years
measure: Myocardial Ischemia measuring ejection fraction.
timeFrame: 5 years
measure: Myocardial Ischemia measuring heart inflow Doppler.
timeFrame: 5 years
Secondary outcomes:
measure: Scarring and fibrosis by measuring Late Gadolinium Enhancement results.
timeFrame: 5 years
measure: Scarring and fibrosis by measuring systolic and diastolic function.
timeFrame: 5 years
measure: Comparison of MRI measurements with blood test.
timeFrame: 5 years
measure: Comparison of MRI measurements with walk test.
timeFrame: 5 years
measure: Comparison of MRI measurements with NY Heart Association class
timeFrame: 5 years
Other outcomes:
Locations:
city: Washington
country: United States
facility: Children's National Health System
state: District of Columbia
Study officials:
affiliation: Children's National Health Systems
name: Laura Olivieri, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk AP, Vliegen HW, Grobbee DE, Mulder BJ. Mortality in adult congenital heart disease. Eur Heart J. 2010 May;31(10):1220-9. doi: 10.1093/eurheartj/ehq032. Epub 2010 Mar 5.
citation: Rutledge JM, Nihill MR, Fraser CD, Smith OE, McMahon CJ, Bezold LI. Outcome of 121 patients with congenitally corrected transposition of the great arteries. Pediatr Cardiol. 2002 Mar-Apr;23(2):137-45. doi: 10.1007/s00246-001-0037-8. Epub 2002 Feb 19.
citation: Meijboom F, Szatmari A, Deckers JW, Utens EM, Roelandt JR, Bos E, Hess J. Long-term follow-up (10 to 17 years) after Mustard repair for transposition of the great arteries. J Thorac Cardiovasc Surg. 1996 Jun;111(6):1158-68. doi: 10.1016/s0022-5223(96)70217-9.